Abstract
High-dose melphalan (MEL) with autologous stem cell transplant (SCT) is an effective therapy for systemic light-chain amyloidosis (AL) and a risk-adapted approach to MEL dosing minimizes transplant-related mortality (
BJH
2007
; 139
Leukemia Lymphoma
2000
;37
:245
Disclosures: No relevant conflicts of interest to declare.
Author notes
Corresponding author
2008, The American Society of Hematology
2008